Error message

Deprecated function: implode(): Passing glue string after array is deprecated. Swap the parameters in drupal_get_feeds() (line 394 of /home/richardb/public_html/sites/vw-staging/includes/common.inc).

Healthcare

Inovio Pharma doubles immune response rate in elderly patients during phase 1 universal flu vaccine trial

December 12, 2012 at 17:37 CST

Inovio Pharmaceuticals (NYSE MKT: INO) reported Monday that preliminary results from a phase I trial of its H1N1 universal flu vaccine in elderly patients showed a doubling of the response rate of subjects generating infection-preventing antibodies.

The company's H1N1 universal SynCon vaccine, followed by a dose of a seasonal flu vaccine, generated protective immune responses in 40 per cent of trial subjects, compared with a 20 per cent response rate in elderly patients who received the seasonal flu vaccine alone.